Blood-Based Biomarkers for Predicting Immunotherapy Benefit in Lung Cancer.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 33064985.
- Also identified by DOI 10.1016/j.cell.2020.09.052.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
PD1/PD-L1-directed immunotherapy, alone or in combination with chemotherapy, dominates the initial treatment of metastatic non-small cell lung cancer. However, our ability to predict who will benefit from these approaches is limited. In this issue of Cell, Nabet et al. report a novel, blood-based methodology to more accurately predict durable disease control with immunotherapy.
Medical subject headings
- Carcinoma, Non-Small-Cell Lung
- Lung Neoplasms